




---

# 2021 3rd Quarter Analyst Briefing

26 Oct 2021





# Disclaimer

---

This presentation has been prepared by Unisem (M) Berhad ("Unisem" or the "Company") solely for use at the Company's quarterly analyst briefing held virtually on 26 Oct 2021. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. The Company or any of its affiliates, advisors or representatives expressly disclaims any and all liability (whether direct or indirect, contract, tort or otherwise) for any losses or liabilities howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. The contents of this presentation may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

This presentation made by representatives of the Company includes certain statements that are not descriptions of historical facts, but are forward-looking statements. These forward-looking statements may include statements about our plans and objectives for future expansion and operations, and other statements containing forward looking terminology such as "may," "believes," "anticipates," "intends," "expects," "projects," "looking forward," "targets," "plans," or similar terms, variations of such terms or the negative of such terms. Such information is based upon various assumptions made by, and expectations of, our management that were reasonable when made but may prove to be incorrect. All of such assumptions are inherently subject to uncertainties and contingencies beyond our control and upon assumptions with respect to future business decisions which are subject to change. Accordingly, there can be no assurance that actual results will meet expectations and actual results may vary (perhaps materially) from certain of the results anticipated herein. The Company undertakes no obligation, and disclaims any obligation, to publicly update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.



# Consolidated Statements of Profit or Loss (From Continuing Operations)

## Sequential Quarterly Comparison

(RM Thousand except EPS)

	<b>3Q 2021</b>	<b>%</b>	<b>2Q 2021</b>	<b>%</b>	<b>Change</b>
<b>Revenue</b>	366,356	100.0	402,233	100.0	-8.9%
<i>Revenue in USD '000</i>	<i>87,394</i>		<i>97,465</i>		<i>-10.3%</i>
<b>Cost of Sales</b>	307,990	84.1	326,525	81.2	-5.7%
<b>Gross Profit</b>	58,366	15.9	75,708	18.8	-22.9%
<b>Operating profit</b>	45,710	12.5	60,058	14.9	-23.9%
<b>Net profit</b>	40,422	11.0	54,754	13.6	-26.2%
<b>EPS – Basic (sen)</b>	5.01		6.81		
<b>EBITDA</b>	94,207	25.7	108,856	27.1	-13.5%
<b>Depreciation</b>	48,497	13.2	48,797	12.1	-0.6%
<b>Forex gain/(loss)</b>	517	0.1	(2,241)	(0.6)	123.1%



## Consolidated Statements of Profit or Loss (From Continuing Operations)

Corresponding Quarterly Comparison

(RM Thousand except EPS)

	<b>3Q 2021</b>	<b>%</b>	<b>3Q 2020</b>	<b>%</b>	<b>Change</b>
<b>Revenue</b>	366,356	100.0	357,681	100.0	2.4%
<i>Revenue in USD '000</i>	<i>87,394</i>		<i>85,098</i>		<i>2.7%</i>
<b>Cost of Sales</b>	307,990	84.1	283,454	79.2	8.7%
<b>Gross Profit</b>	58,366	15.9	74,227	20.8	-21.4%
<b>Operating profit</b>	45,710	12.5	55,656	15.6	-17.9%
<b>Net profit</b>	40,422	11.0	49,445	13.8	-18.2%
<b>EPS – Basic (sen)</b>	5.01		6.80		
<b>EBITDA</b>	94,207	25.7	98,479	27.5	-4.3%
<b>Depreciation</b>	48,497	13.2	42,823	12.0	13.2%
<b>Forex gain/(loss)</b>	517	0.1	(4,777)	-1.3	110.8%



## Consolidated Statements of Profit or Loss (From Continuing Operations)

Corresponding 9-Month Comparison

(RM Thousand except EPS)


	<b>9m 2021</b>	<b>%</b>	<b>9m 2020</b>	<b>%</b>	<b>Change</b>
<b>Revenue</b>	1,142,527	100.0	922,923	100.0	23.8%
<i>Revenue in USD '000</i>	<i>276,814</i>		<i>218,221</i>		<i>26.9%</i>
<b>Cost of Sales</b>	945,723	82.8	773,289	83.8	22.3%
<b>Gross Profit</b>	196,804	17.2	149,634	16.2	31.5%
<b>Operating profit</b>	156,663	13.7	108,522	11.8	44.4%
<b>Net profit</b>	140,969	12.3	88,674	9.6	59.0%
<b>EPS – Basic (sen)</b>	17.60		12.20		
<b>EBITDA</b>	300,839	26.3	231,176	25.0	30.1%
<b>Depreciation</b>	144,176	12.6	122,653	13.3	17.5%
<b>Forex loss</b>	(1,279)	(0.11)	(667)	-0.1	91.8%



# 3Q 2021 Revenue & EBITDA

(From Continuing Operations)

- RM Revenue : RM366.4m vs RM402.2m (-8.9%)
- USD revenue : USD87.4m vs USD97.5m (-10.3%)
- EBITDA : RM94.2m vs RM108.9m (-13.5%)
- EBITDA margin : 25.7% vs 27.1 % (-5.2%)








# Revenue Breakdown

Increase in WL Packaging/FC/BGA

## By Products & Services








# Revenue Breakdown

Decline in contribution from Comm segment - Ipoh plant closures

By Market Segments





# Selective Information from Consolidated Statements of Financial Position

Net cash at end Sep 2021: RM622.5 million

(in RM Thousand)

	<b>30 Sept 2021</b>	<b>31 Dec 2020</b>	<b>Change</b>
<b>Property plant &amp; equipment</b>	1,535,117	1,215,064	26.3%
<b>Cash and Bank Balances</b>	792,523	664,095	19.3%
<b>Group term loan &amp; bank borrowings</b>	170,039	207,400	-18.0%
<b>Net Assets per share (RM)</b>	2.6426	2.2766	16.1%

<b>Current ratio</b>	2.52	3.17	-20.5%
<b>Debt/equity ratio</b>	0.08	0.12	-33.3%



# Capex & Headcount

- Capex incurred in 3Q21: RM134.3m mainly to increase capacity for assembly and test in Chengdu and Ipoh
- Group Headcount was at 6,078 in end Sept 2021. Headcount decrease at Ipoh plant.

	3Q19	4Q19	1Q20	2Q20	3Q20	4Q20	1Q21	2Q21	3Q21
Capex (RMmil)	34.0	15.1	84.8	81.7	49.9	54.5	137.7	156.0	134.3
Headcount	7,151	7,063	6,810	5,966	5,892	5,738	6,139	6,148	6,078



# 3Q 2021 Highlight

---

- Completed Bonus Issue of 1 for 1 on 8th Oct 2021.
- Closure of Unisem Ipoh plant for sanitising from 8th to 14th Sep 2021.
- Utilisation rates remain high in Chengdu plant, both in wafer bumping and assembly & test. Phase 3 plant construction has started.
- Assembly & test operations in Ipoh plant & UAT were disrupted by closures in July/Aug and Sept. Headcount limitation of 60% imposed (quarantine of operators due to close contact). About 99.9% of our employees have now been fully vaccinated. Expect the workforce/attendance to normalise in early Q4.
- Utilisation rates at wafer bumping operations in UAT below optimal due to wafer shortage.



---

# Thank You

“Proven Technologies, Innovative Processes”